McKesson Corporation
Rating
Updated: Sep 18, 2026Why Price Moved
Shares are trading higher after McKesson raised it...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organize...
Latest News
4 days ago · zacks.com
McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to KnowMcKesson (MCK) closed at $887.29 in the latest trading session, marking a -1.36% move from the prior day.
7 days ago · seekingalpha.com
McKesson Corporation (MCK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptMcKesson Corporation (MCK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
7 days ago · marketbeat.com
McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine DealMcKesson NYSE: MCK executives said the company's first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions businesses.
10 days ago · defenseworld.net
Baird Financial Group Inc. Has $29.98 Million Holdings in McKesson Corporation $MCKBaird Financial Group Inc. lifted its holdings in shares of McKesson Corporation (NYSE: MCK) by 4.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,670 shares of the company's stock after buying an additional 1,553 shares during
10 days ago · defenseworld.net
McKesson Corporation $MCK Shares Sold by Allworth Financial LPAllworth Financial LP cut its stake in McKesson Corporation (NYSE: MCK) by 14.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,498 shares of the company's stock after selling 910 shares during the quarter. Allworth Financial LP's holdings in McKesson
11 days ago · zacks.com
McKesson (MCK) Suffers a Larger Drop Than the General Market: Key InsightsMcKesson (MCK) closed at $880.86 in the latest trading session, marking a -1.21% move from the prior day.
12 days ago · zacks.com
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on ItMcKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
13 days ago · seekingalpha.com
McKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptMcKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
13 days ago · marketbeat.com
McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth AcceleratesMcKesson NYSE: MCK discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter.
14 days ago · seekingalpha.com
Underestimating The Moat: Why McKesson's Oncology Pivot And Share Buybacks Signal Structural UpsideMcKesson operates within a US pharma distribution oligopoly, generating $5B+ in FCF and aggressively repurchasing shares. The oncology segment is driving growth, with a 31% YoY revenue increase and strategic acquisitions reinforcing the shift toward higher-margin businesses. Despite negative shareholder equity from buybacks and opioid liabilities, MCK maintains strong liquidity, low leverage, and disciplined capital returns.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MCK